Strategic Report Our performance at a glance Europe, Middle East Asia Pacific and Africa Revenue 30.5% 22% 305.3m 218.0m Reported Organic Reported Organic 30% 13% 5% 6% Operating profit 66.1m 56.9m Operating margin 21.7% 26.1% No.
of operating units 33 14 at year end operating units operating units Key industries Organic sales up 5%: organic operating Organic sales up 6%: organic operating Performance summary profit up 7%.
Currency tailwind of 5% on profit up 7%.
China performed strongly, sales and 11% on profit.
Strong sales self-generated sales drive growth.
growth in Italy, France, Iberia, Benelux and Solid growth in Korea driven by large Oil Middle East.
Sales broadly flat in Germany: & Gas project.
India progressing well: UK and Nordics down.
Gestra integrating doubled sales, increased manufacturing well: adds 19% to sales, 13% to profit.
China plant extension Margin 40 bps higher: 140 bps excluding completed: new Singapore distribution acquisition.
Remain confident in our ability centre.
Margin up 30 bps: up 60 bps to deliver above market growth.
Well positioned to make further progress.
Read more on pages 38-39 Read more on pages 40-41 Unless otherwise stated, all profit measures exclude certain items, as set out and explained in the Financial Review and in Note 2 on page 129.
Organic measures are at constant currency and exclude acquisitions.
36 Spirax-Sarco Engineering plc Annual Report 2017 Strategic Report Fluid Technology Group Americas Chromalox Watson-Marlow Acquired July 2017 25% 7.5% 15% 152.1m 75.1m 248.2m Reported Organic Reported Organic 12% 28% 2% 10% 31.6m 13.8m 80.3m 20.8% 18.4% 32.4% 10 15 38 operating units operating units operating units Organic sales up 2%: organic operating Since acquisition July : 75.1m sales, Organic sales up 10%: benefited from profit up 1%.
Full year performance 2016 order book.
Strong growth in all growth in distribution: end user projects 2017 in line with expectations.
Strong H2 regions: APAC, LATAM very strong.
Latin America: 6% organic 2017 demand, good growth on H2 2016.
Pharma & Biotech sector up against growth: Mexico, Argentina up, Brazil Strong sales and profit growth in Q4 2017. tough compare.
Excellent growth in marginally down.
Hiter making excellent Integration progressing well: investing for Food & Beverage with Certa pump.
progress: H2 2017 profit ahead of growth.
Margin ahead of 2016: 18.4% Aflex acquisition performing well: boosts schedule.
Organic margin flat: dilutionary post-acquisition.
Profit up 6% organically: effect from acquisitions and currency.
FX offsets investments for growth.
Focus on efficiency improvements to Margin down 70 bps due to Aflex offset exchange headwinds in 2018. dilution.
Increased R&D spend: small Well positioned to make further progress.
Read more on pages 42-43 Read more on pages 44-45 Read more on pages 46-47 Spirax-Sarco Engineering plc Annual Report 2017 37 Corporate Information Financial Statements Governance Report Strategic Report
